NCT01673178 - Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2013

Conditions

Diabetes Melliuts, Type 2

Interventions

OTHER

Placebo

0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks

DRUG

25 mg PF-05231023

25 mg IV once a week for 4 weeks

DRUG

50 mg PF-05231023

50 mg IV once a week for 4 weeks

DRUG

100 mg PF-05231023

100 mg IV once a week for 4 weeks

DRUG

150 mg PF-05231023

150 mg IV once a week for 4 weeks

Trial Locations (17)

27265

High Point Clinical Trials Center, LLC, High Point

27612

Carolina Phase 1 Research, Raleigh

Wake Internal Medicine Consultants, Raleigh

32720

Avail Clinical Research, LLC, DeLand

33143

Miami Research Associates, Inc., South Miami

MRA Clinical Research, LLC, South Miami

33169

Elite Research Institute, Miami

40213

L-MARC Research Center, Louisville

40509

Central Kentucky Research Associates, Inc., Lexington

45227

Medpace Clinical Pharmacology Unit, Cincinnati

45255

Community Research, Cincinnati

Mercy Hospital Pharmacy, Cincinnati

55114

Prism Research, Saint Paul

75247

Covance Clinical Research Unit, Dallas

91911

Profil Institute for Clinical Research, Inc., Chula Vista

92801

Anaheim Clinical Trials, LLC, Anaheim

94598

Diablo Clinical Research, Inc., Walnut Creek